Dr Reddy’s Laboratories is trading higher by 2% at Rs 2,635 after drug maker said that it has launched generic version of Pfizer's Caduet tablets, a cholesterol-lowering drug, in US market.
The company has launched Amlodipine Besylate and Atorvastatin Calcium Tablets, a therapeutic equivalent generic version of Caduet (amlodipine besylate and atorvastatin calcium) tablets, in the US market, following the approval by the United States Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a statement.
According to IMS Health sales data, Caduet tablets brand and generics had US sales of around $163 million for the most recent twelve months ending in January 2014.
The stock opened at Rs 2,600 and touched a high of Rs 2,637 on the BSE. A combined 106,000 shares changed hands on the counter so far on the BSE and NSE.
The company has launched Amlodipine Besylate and Atorvastatin Calcium Tablets, a therapeutic equivalent generic version of Caduet (amlodipine besylate and atorvastatin calcium) tablets, in the US market, following the approval by the United States Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a statement.
According to IMS Health sales data, Caduet tablets brand and generics had US sales of around $163 million for the most recent twelve months ending in January 2014.
The stock opened at Rs 2,600 and touched a high of Rs 2,637 on the BSE. A combined 106,000 shares changed hands on the counter so far on the BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%